PopMuse: Disease and Disability http://popmu.se Musings of stuff en-us Copyright 2007-2020 http://creativecommons.org/licenses/by-nc-sa/3.0/ TV Shows Starring Actors With Developmental Disabilities Set To Return https://www.disabilityscoop.com/2020/06/01/tv-shows-starring-actors-with-developmental-disabilities-set-to-return/28392/ https://www.disabilityscoop.com/2020/06/01/tv-shows-starring-actors-with-developmental-disabilities-set-to-return/28392/ Mon, 01 Jun 2020 04:01:43 UTC Shaun Heasley at Disability Scoop Television network executives say they will bring back two shows that prominently feature actors who have developmental disabilities. http://creativecommons.org/licenses/by-nc-sa/3.0/ [Correspondence] The health-related determinants of politics https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30555-9/fulltext?rss=yes https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30555-9/fulltext?rss=yes Sat, 30 May 2020 00:00:00 UTC Parth Patel at The Lancet I was pleased to read Richard Horton's Comment about populist politics.1 However, the problem of political populism and solution that he charts out seem somewhat non-sequitur. http://creativecommons.org/licenses/by-nc-sa/3.0/ [Comment] Offline: After COVID-19—is an “alternate society” possible? https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31241-1/fulltext?rss=yes https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31241-1/fulltext?rss=yes Sat, 30 May 2020 00:00:00 UTC Richard Horton at The Lancet How do we make sense of this pandemic? The first interpretations are now appearing. Slavoj Žižek is a prolific philosopher and cultural theorist. He is the first to produce a volume of reflections—Pandemic! COVID-19 Shakes the World (Polity, 2020). Žižek doubts the epidemic will make us wiser: he insists that “we should resist the temptation to treat the ongoing epidemic as something that has a deeper meaning”. Despite these cautions, we still have an important question to answer: “What is wrong with our system that we were caught unprepared by the catastrophe despite scientists warning us about it for years?” We must accept that “The coronavirus epidemic itself is clearly not just a biological phenomenon which affects humans: to understand its spread, one has to consider human cultural choices…economy and global trade, the thick network of international relations, ideological mechanisms of fear and panic.” Žižek opens his investigation in China—“China thwarts the freedoms of its citizens.” He endorses the view of Li Wenliang, the ophthalmologist who was censored by Wuhan authorities for sharing information about the new SARS-CoV-2 virus and who later died from COVID-19: “There should be more than one voice in a healthy society.” China dealt assertively and successfully with the outbreak in Wuhan. http://creativecommons.org/licenses/by-nc-sa/3.0/ [Department of Error] Department of Error https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31205-8/fulltext?rss=yes https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31205-8/fulltext?rss=yes Sat, 30 May 2020 00:00:00 UTC The Lancet McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet 2020; 395: 1496–505—The appendix of this Article has been corrected as of May 28, 2020. http://creativecommons.org/licenses/by-nc-sa/3.0/ [Department of Error] Department of Error https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31195-8/fulltext?rss=yes https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31195-8/fulltext?rss=yes Sat, 30 May 2020 00:00:00 UTC The Lancet Gaudinski MR, Coates EE, Novik L, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet 2019; 393: 889–98—In figure 2 of this Article, in part C, the group three serum concentration on day 14 should have been 629·32 μg/mL (SD 118·19). This correction has been made to the online version as of May 28, 2020. http://creativecommons.org/licenses/by-nc-sa/3.0/ [Department of Error] Department of Error https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31018-7/fulltext?rss=yes https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31018-7/fulltext?rss=yes Sat, 30 May 2020 00:00:00 UTC The Lancet Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 2020; 395: 1278–91—In this Article, the second instance of obinutuzumab in the title was misspelled and has been corrected. In table 1, the row labelled Chromosome 17p13·1 deletion or mutated TP53 has been corrected to Chromosome 17p13·1 deletion and/or mutated TP53, and data in this row have been updated. http://creativecommons.org/licenses/by-nc-sa/3.0/ [Editorial] COVID-19 in Africa: no room for complacency https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31237-X/fulltext?rss=yes https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31237-X/fulltext?rss=yes Sat, 30 May 2020 00:00:00 UTC The Lancet at The Lancet Despite over 100 000 confirmed cases and infections in every country, the passage of COVID-19 through the African continent remains somewhat enigmatic. High numbers of deaths were expected in the region due to fragile health systems, lack of access to preventive measures, barriers to testing, and potentially vulnerable populations. But, according to WHO, Africa is the least affected region globally, with 1·5% of the world's reported COVID-19 cases and 0·1% of the world's deaths. Although comparisons are inaccurate, mortality rates have been lower compared with outbreaks of similar size elsewhere. http://creativecommons.org/licenses/by-nc-sa/3.0/ [Clinical Picture] Drusen in dense deposit disease: not just age-related macular degeneration https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30976-4/fulltext?rss=yes https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30976-4/fulltext?rss=yes Sat, 30 May 2020 00:00:00 UTC Daniella Lent-Schochet, Glenn Yiu at The Lancet A 40-year-old woman was referred to our clinic by her optometrist because she had lesions on her retina suggestive of age-related macular degeneration (AMD). She was otherwise well: with no systemic or visual symptoms. http://creativecommons.org/licenses/by-nc-sa/3.0/ [Correspondence] Towards more balanced representation in Lancet Commissions https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30617-6/fulltext?rss=yes https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30617-6/fulltext?rss=yes Sat, 30 May 2020 00:00:00 UTC Manuel W Hetzel, Bassirou Bonfoh at The Lancet Enthusiastically, Richard Horton1 reports on the foundation of the Italian Institute of Planetary Health at a time when youth strikes, an emerging pandemic of a new coronavirus, and burning forests remind us of our planet being in jeopardy. We agree that something must change so that the undoubtable advances in science and medicine that were made since the time of Lucretius translate into a better life for all humans, no matter who they are, where they were born, and where they live and work.1 Yet, the lamented crisis of trust in science and medicine cannot be overcome by concepts of global health or planetary health unless their actors truly embrace the planetary concept and approaches. http://creativecommons.org/licenses/by-nc-sa/3.0/ [Department of Error] Department of Error https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31021-7/fulltext?rss=yes https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31021-7/fulltext?rss=yes Sat, 30 May 2020 00:00:00 UTC The Lancet Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 2019; 394: 1940–48—In this Article, the Declaration of interests have been corrected for Karen S McCoy, Bonnie W Ramsey, Steven M Rowe, and John J Welter. These corrections have been made to the online version as of May 28, 2020. http://creativecommons.org/licenses/by-nc-sa/3.0/